pSivida names new president and CEO
Dr Ashton joined pSivida in December 2005 following the acquisition of Control Delivery Systems where he was co-founder, president, CEO, and a member of the board of directors.
Akeso has received approval from China’s National Medical Products Administration (NMPA) for gumokimab (AK111), an anti-Interleukin-17 (IL-17) monoclonal antibody, to treat adults with moderate-to-severe plaque psoriasis.